Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation

Trial Profile

Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Selinexor (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Feb 2018 Status changed to active, no longer recruiting.
    • 12 Dec 2017 Results (n=9) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Nov 2017 According to a Karyopharm Therapeutics media release, updated data from this trial will be presented at the American Society of Hematology (ASH) 2017 annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top